Idelalisib (CAL-101, GS-1101)

製品コードS2226

Idelalisib (CAL-101, GS-1101)化学構造

分子量(MW):415.42

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

サイズ 価格(税別)  
JPY 25896.00
JPY 19920.00
JPY 78020.00

文献中Selleckの製品使用例(31)

カスタマーフィードバック(5)

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Ppp2r1afl/fl BCR-ABL1 B-ALL cells transduced with 4-OHT-inducible Cre-ERT2 (Cre) or ERT2-vector (EV) were treated with 4-OHT for 3 days and cell lysates were studied by phospho-protein array analysis. Ppp2r1afl/fl BCR-ABL1 ALL cells were transduced with 4-OHT-inducible Cre or EV control and incubated in the presence of the small molecule signaling inhibitor idelalisib (32 μmol/L; C). Percentages of GFP+ cells were measured by flow cytometry at the times indicated following 4-OHT-treatment. Data are shown as mean ± standard deviation (SD) and representative of at least three independent experiments.

    Cell, 2018, 173(2):470-484. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • 293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
ターゲット
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外試験

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. [1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. [2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 NGGzRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMSG1UVw>? M4DYU2lEPTB;MkCuOEDPxE1? MmP5NlU6QTl|NUK=
CLL PBMCs MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7FSG1UVw>? M1TXcGlEPTB;Mj65JI5O NX[wc4JmOjV7MUeyOlc>
U266 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fJPVQxKM7:TR?= MVq0PEBp NYDBcm06PzlwNTWgbY5pcWKrdHnvckBz[XSn NGLycJEzPTN|OUOzNi=>
K562 M3zGZmZ2dmO2aX;uJGF{e2G7 MVyxJO69VQ>? NEi5T5M{KGh? NYi1T|NbUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NGq2TXYzPTBzNEe3OS=>
K562 MV3GeY5kfGmxbjDBd5NigQ>? MkXJNUDPxE1? M4rUSlMhcA>? M3u0d2lvcGmkaYTpc44hd2ZiUEewV|ZMKHCqb4PwbI9zgWyjdHnvci=> M1;2b|I2ODF2N{e1
K562 NV[0e2NPTnWwY4Tpc44hSXO|YYm= M1HUWVEh|ryP MXOzJIg> M{m1eGlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= NHm2N2gzPTBzNEe3OS=>
K562 NVr0Z4tXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjtW|k4OSEQvF2= Mn;KO|IhcA>? MlLkTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u MnXyNlUxOTR5N{W=
Primary AML cell MWPGeY5kfGmxbjDBd5NigQ>? MU[xJO69VQ>? M4XzUlMhcA>? M4HsNmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= M1XwVVI2ODF2N{e1
Primary AML cell M2\pWGZ2dmO2aX;uJGF{e2G7 M4rDRVEh|ryP NIr2OFg{KGh? NGLGN5hKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> NYHzcnloOjVyMUS3O|U>
Primary AML cell M4n3OGZ2dmO2aX;uJGF{e2G7 NHK0UIYyKM7:TR?= MUizJIg> M2rpTWlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= MX6yOVAyPDd5NR?=
Primary AML cell NWL5SlBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\GWG0yKM7:TR?= MX6zJIg> MWrTeZBxemW|c3nvckBw\iC{Ul7BJJN6dnSqZYPpdy=> M2rKSVI2ODF2N{e1
Microglia M4SwdmZ2dmO2aX;uJGF{e2G7 MXO1JO69VQ>? M{nSeVExKGh? NFHhNYpFVVOR M1fX[WRm[3KnYYPlJI9nKFSQRnGgd4VkemW2aX;uJIZzd21iTGDTMZN1cW23bHH0[YQhKHBzMUFOuGQ6OTCDL1S5NVBCKG2rY4Lv[4xq[Q>? MXyyOFYzPTZ6NB?=
Primary CLL cell NX7JPW82TnWwY4Tpc44hSXO|YYm= MkTGNUDPxE1? MWSxOUBucW5? NYjHT3VmTE2VTx?= Mn;WRoxw[2u|IFLDVk1qdmS3Y3XkJGxEWDFic3XybY5mNTViYXP0bZZifGmxbh?= NGqx[GIzPDByOUKzNy=>
JEKO-1 NYjYZYoyTnWwY4Tpc44hSXO|YYm= M{S2eVEh|ryP MXO3NkBp M1zOVGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? MXiyN|M1OTV2MR?=
Granta-519 M2Ljb2Z2dmO2aX;uJGF{e2G7 M2TPVlEh|ryP NH[weIUzKGh? MkfJTY5pcWKrdHnvckBw\iCDa4SoeFMxQClicHjvd5Bpd3K7bHH0bY9v NXXD[JBWOjN|NEG1OFE>
Granta-519 MorGSpVv[3Srb36gRZN{[Xl? M2TqWlEh|ryP M{HFeFIhcA>? NH\s[nJKdmirYnn0bY9vKG:oIFHreEh{PDd|KTDwbI9{eGixconsZZRqd25? NGH5cYMzOzN2MUW0NS=>
JEKO-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rRVVExKM7:TR?= NH3VeJU4OiCq NF\KO2dKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk> MmjDNlM{PDF3NEG=
JEKO-1 NUHWVpJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXkOUDPxE1? NF\LTo04OiCq MVHkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz M3zzVlI{Pjd4MkKw
MAVER-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW1JO69VQ>? NXPGUWdYPzJiaB?= M3PMRYRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> NYjvUW5ZOjN4N{[yNlA>
MINO NXfuPVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\T[nJrPSEQvF2= NHT1N244OiCq NELtRYhld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ M1O3eFI{Pjd4MkKw
SP53 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXaSnhMOC5zIN88US=> NH[yWG44OiCq MmnJ[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=> M3\BbVI{Pjd4MkKw
HH MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTMcpIyOTBizszN MYK3NkBp MXHEUXNQ NWrGd|d[UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDzcIlocHSueR?= NEDSXlgzOjhyMUm1PS=>
Myla MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MneyNVAh|ryP Ml\BO|IhcA>? M3HCXWROW09? M1:xToRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MYGyNlgxOTl3OR?=
SR786 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? MYq3NkBp NGTFR4dFVVOR NVPFUpU1\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> M2T5[lIzQDBzOUW5
HuT78 NFXEZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLVNVAh|ryP M17YNlczKGh? NGGzdWpFVVOR MUTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| MoXXNlI5ODF7NUm=
MJ Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLoNpEyOCEQvF2= NG\FTmE4OiCq NV3SRXBjTE2VTx?= Ml\u[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NVXBbXRtOjJ6MEG5OVk>
DERL7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnSNVAh|ryP NIS1O2w4OiCq M{LnfmROW09? MYnkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| MWqyNlgxOTl3OR?=
L1236 NV;LTYNOTnWwY4Tpc44hSXO|YYm= MYOxNEDPxE1? M3v4N|IhcA>? MUnJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NWPMO5BMOjJ{MUC4O|c>
L428 MYDGeY5kfGmxbjDBd5NigQ>? NHexZpMyOCEQvF2= MnvZNkBp NH64N5hKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= M3\tcVIzOjFyOEe3
L591 M1jHUWZ2dmO2aX;uJGF{e2G7 NWK3[3RROTBizszN NHv2WJAzKGh? NXLObmhQUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u M3\mW|IzOjFyOEe3
KMH-2 NFv4SYVHfW6ldHnvckBCe3OjeR?= MWGxNEDPxE1? M2XzclIhcA>? M3H5UWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= MXmyNlIyODh5Nx?=
L1236 M2L0UGZ2dmO2aX;uJGF{e2G7 NWGwSGR6PSEQvF2= NImyZo8zPCCq MVLCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 NI\IblEzOjJzMEi3Oy=>
L591 MY\GeY5kfGmxbjDBd5NigQ>? MYm1JO69VQ>? M{LFUlI1KGh? MlK4Roxw[2u|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=> NU\jZYtxOjJ{MUC4O|c>
L1236 NFfZbY5CeG:ydH;zbZMhSXO|YYm= MXK1JO69VQ>? NET1fWQzPCCq NEHJR2ZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| MnXTNlIzOTB6N{e=
L591 M{W1RmFxd3C2b4Ppd{BCe3OjeR?= M3:2W|Uh|ryP MYCyOEBp M4DETWlv\HWldHnvckBw\iCjcH;weI9{cXN? M4rmU|IzOjFyOEe3
U-87MG MUTGeY5kfGmxbjDBd5NigQ>? MX6xNFAhdk1? M3r5e|I1KGh? M{LZWGROW09? NF[zTFBKdmirYnn0bY9vKG:oIDDj[YxtKG2rZ4LheIlwdg>? MoHRNlIxPzl4MEm=
SW1783 MWXGeY5kfGmxbjDBd5NigQ>? M3vRZVExOCCwTR?= MoTVNlQhcA>? M3TPPWROW09? MnjuTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> M4fUbFIzODd7NkC5
U-87MG MkDISpVv[3Srb36gRZN{[Xl? Mnj1OUDPxE1? MUiyOEBp NHWy[nNFVVOR NFnlRoxKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? M4DzXlIzODd7NkC5
SW1783 MV\GeY5kfGmxbjDBd5NigQ>? M13mR|Uh|ryP M1y4[lI1KGh? M3XhZ2ROW09? NWnuOINCUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? MmnmNlIxPzl4MEm=
U-373MG MYTGeY5kfGmxbjDBd5NigQ>? NVHaZlB2PSEQvF2= MVKyOEBp M3nJWmROW09? Ml6zTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> NG\PNmgzOjB5OU[wPS=>
SK-MG3 M3WxRWZ2dmO2aX;uJGF{e2G7 NGPZUG82KM7:TR?= NF30c5czPCCq M3TDWGROW09? NHjaSHpKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? NYjPXm9nOjJyN{m2NFk>
SU-DHL-5 NYfrbYZ{TnWwY4Tpc44hSXO|YYm= NHvGUFYyKM7:TR?= MWWyOEBp NXXTTlBNTE2VTx?= MlLzTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? MUCyNFk2QTZyNh?=
WSU-NHL NFjh[HFHfW6ldHnvckBCe3OjeR?= MlzZNUDPxE1? M17qb|I1KGh? MlT0SG1UVw>? NEDTUmFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| NGLSTVAzODl3OU[wOi=>
CCRF-SB MkfFSpVv[3Srb36gRZN{[Xl? NV:xZVRbOSEQvF2= NULjZ4R7OjRiaB?= NX7KOXQ1TE2VTx?= M1nrb2lv\HWldHnvckBw\iCjcH;weI9{cXN? NI\meIIzODl3OU[wOi=>
INA-6 NV2zeFZ{TnWwY4Tpc44hSXO|YYm= NVjBenJwPSEQvF2= NUDpNZVvPiCq NIHCUmZKdmirYnn0bY9vKG:oIGDJN2swSWu2IHHu[EBGWkticHH0bJdigQ>? Mn7sNlA2ODVzNUi=
LB MWHGeY5kfGmxbjDBd5NigQ>? MVy1JO69VQ>? NH7Dd403KGh? NEThd|VKdmirYnn0bY9vKG:oIGDJOGswSWu2IHHu[EBGWkticHH0bJdigQ>? NVTtRYNEOjB3MEWxOVg>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

お薦めの試験操作(参考用のみ)

キナーゼ試験:[2]
+ 展開

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
細胞試験: [2]
+ 展開
  • 細胞株: CLL B cells or healthy volunteer T cells or NK cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ: MTT assays are performed to determine cytotoxicity. 1 × 105 cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm2 flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 83 mg/mL (199.79 mM) warming
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
混合させたのち直ちに使用することを推奨します。
30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 415.42
化学式

C22H18FN7O

CAS No. 870281-82-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03576443 Recruiting Diffuse Large B Cell Lymphoma Nordic Lymphoma Group July 7 2017 Phase 2
NCT02962401 Active not recruiting Waldenstrom Macroglobulinemia French Innovative Leukemia Organisation March 7 2017 Phase 2
NCT02044822 Terminated B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Gilead Sciences August 6 2014 Phase 2
NCT02436135 Completed Myelofibrosis Gilead Sciences June 5 2015 Phase 1
NCT01980888 Terminated Chronic Lymphocytic Leukemia Gilead Sciences February 5 2014 Phase 3
NCT02739360 Completed Lymphoid Malignancies Gilead Sciences May 4 2016 Phase 4

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: Idelalisib (CAL-101, GS-1101)を買う | Idelalisib (CAL-101, GS-1101) ic50 | Idelalisib (CAL-101, GS-1101)供給者 | Idelalisib (CAL-101, GS-1101)を購入する | Idelalisib (CAL-101, GS-1101)費用 | Idelalisib (CAL-101, GS-1101)生産者 | オーダーIdelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)化学構造 | Idelalisib (CAL-101, GS-1101)分子量 | Idelalisib (CAL-101, GS-1101)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID